No Data
Is Frontier Biotechnologies (SHSE:688221) Weighed On By Its Debt Load?
Frontier Biotech (688221.SH) subsidiary sichuan frontier passes the pharmaceutical GMP compliance inspection.
Frontier Biotechnology (688221.SH) announced that the company has received the approval and issuance of supplementary pharmaceuticals by the National Medical Products Administration...
Frontier Biotech (688221.SH): Aikening's new maintenance treatment indication obtained the Phase II clinical trial approval notice.
Frontbio (688221.SH) announced on November 5th that the company has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing the company to conduct a Phase II clinical trial for expanding the indications of its marketed product EKoning for maintenance therapy according to the submitted plan. EKoning is a domestically developed Class 1.1 new drug, the world's first long-acting HIV fusion inhibitor approved in the major global markets with independent intellectual property rights. EKoning, when used in combination with other antiretroviral drugs, is effective against the prevalent HIV-1 virus and resistant viruses, with a reduced dosing frequency.
Frontier Biology: Frontier Biotech Third Quarter 2024 Report
Frontier Biotech 2024 Third Quarter Report
Frontier Biotech (688221.SH): Selling part of the equity of a wholly-owned subsidiary and passively forming external borrowings and guarantees.
Gelonghui October 10th, Front Biosciences (688221.SH) announced that the company holds 100% equity of Sichuan Front Biosciences Co., Ltd. (referred to as Sichuan Front) through its wholly-owned subsidiary Shanghai Qianyan Jianling Biotechnology Co., Ltd. (referred to as Shanghai Jianling); and as the investment subject of Sichuan Front, it has invested in and built a high-end polypeptide active pharmaceutical ingredient production base in Jintang County, Chengdu City, Sichuan Province. In order to focus on the development of the main business and optimize resource allocation, and based on the premise of locking in Sichuan Front as the future entrusted production party of the company's active pharmaceutical ingredients, the company plans to transfer 70% equity of Shanghai Jianling to Tibet Duorui Pharmaceutical Co., Ltd.
